215 related articles for article (PubMed ID: 12590950)
1. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.
Villmow T; Kemkes-Matthes B; Matzdorff AC
Thromb Res; 2002 Nov; 108(2-3):139-45. PubMed ID: 12590950
[TBL] [Abstract][Full Text] [Related]
2. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
Parise P; Huybrechts E; Grasselli S; Falcinelli F; Nenci GG; Gresele P; Vermylen J
Acta Haematol; 1991; 85(2):88-92. PubMed ID: 1902615
[TBL] [Abstract][Full Text] [Related]
3. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
4. [Plasminogenesis in blood of patients with chronic myeloproliferative syndromes].
Rość D; Kremplewska-Nalezyta E; Gadomska G; Drewniak W; Koczubik W
Pol Arch Med Wewn; 2006 Jan; 115(1):23-8. PubMed ID: 17278781
[TBL] [Abstract][Full Text] [Related]
5. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders.
Meschengieser S; Blanco A; Woods A; Maugeri N; Fernandez J; Dupont J; Lazzari MA
Thromb Res; 1987 Nov; 48(3):311-9. PubMed ID: 3501618
[TBL] [Abstract][Full Text] [Related]
6. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
8. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
Strati P; Bose P; Lyle L; Gaw K; Zhou L; Pierce SA; Huynh-Lu J; Hirsch-Ginsberg CF; Bueso-Mendoza DE; Bueso-Ramos CE; Verstovsek S
Ann Hematol; 2017 May; 96(5):733-738. PubMed ID: 28247057
[TBL] [Abstract][Full Text] [Related]
9. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.
Karakantza M; Giannakoulas NC; Zikos P; Sakellaropoulos G; Kouraklis A; Aktypi A; Metallinos IC; Theodori E; Zoumbos NC; Maniatis A
Int J Hematol; 2004 Apr; 79(3):253-9. PubMed ID: 15168594
[TBL] [Abstract][Full Text] [Related]
10. Influence of thrombopoietin on platelet activation in myeloproliferative disorders.
Usuki K; Iki S; Endo M; Izutsu K; Inoue K; Nishimura T; Urabe A
Br J Haematol; 1997 Jun; 97(3):530-7. PubMed ID: 9207394
[TBL] [Abstract][Full Text] [Related]
11. Assessment of platelet activation in myeloproliferative disorders with complementary techniques.
Bermejo E; Alberto MF; Meschengieser SS; Lazzari MA
Blood Coagul Fibrinolysis; 2004 Apr; 15(3):235-40. PubMed ID: 15060419
[TBL] [Abstract][Full Text] [Related]
12. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count.
Jensen MK; de Nully Brown P; Lund BV; Nielsen OJ; Hasselbalch HC
Eur J Haematol; 2001 Mar; 66(3):143-51. PubMed ID: 11350482
[TBL] [Abstract][Full Text] [Related]
13. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
17. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
18. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
19. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
20. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]